Special Issue "Circulating Tumor Cells as Cancer Diagnostic Biomarkers"
Deadline for manuscript submissions: 3 August 2018
Prof. Dr. Dario Marchetti
Director, Biomarker Research Program, Houston Methodist Research Institute, Professor, Institute of Academic Medicine, Visiting Professor, Baylor College of Medicine, MS: R7-414, 6670 Bertner Avenue, Houston, TX 77030, USA
Website | E-Mail
Interests: the biology and therapeutic utility of circulating tumor cells (CTCs); liquid biopsies; mechanisms of brain metastasis and dormancy in breast and melanoma cancers; roles of heparanase in development and disease
The major cause of cancer mortality is metastasis; however, the mechanisms of clinical metastasis remain poorly understood. Because tumor cell dissemination mostly occurs through the blood, deciphering biomarkers, properties and characteristics of circulating tumor cells (CTCs) are of fundamental relevance to develop and implement novel drug therapies in oncology. CTCs can act as “liquid biopsy” to diagnose and monitor cancer in patients in “real time”. They represent clinically useful tools to better reflect cancer progression, nascent metastatic disease, and therapy efficacy in the patient.
There are multiple challenges connected with CTC research and CTC clinical implementation. CTCs are rare, fragile, and heterogeneous, latter either inherited from respective primary/metastatic tumors or as a result of CTC properties interconversion by genetic/epigenetic progression that may or may not lead to a fully metastatic-competent CTC. Significant technical challenges in the field also persist to identify and interrogate CTC heterogeneity, discover CTC biomarkers of clinical utility, and comprehensively capture and interrogate CTCs. Many studies have reported the clinical impact of CTCs since CTC testing has being applied in over 300 clinical trials worldwide. However, much of the CTC biology needs to be discovered and many scientific/technical challenges must be overcome before their clinical promise as biomarkers and targets for improved therapies can be fulfilled.
The objective of this Special Issue is to publish latest findings of CTC research. Contributions outlining CTC discoveries in biological and clinical settings, CTC theoretical and pre-clinical models, CTC technologies and methods for their detection, and clinical findings applying CTC concepts, are welcome.
Prof. Dr. Dario Marchetti
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 550 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Liquid Biopsy
- Cancer metastasis
- The biology and therapeutic utility of CTCs
- CTC technologies
- Tumor dormancy
- Mechanisms of metastasis
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.